News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
UK Study Warns Against Johnson & Johnson (JOBS), Eli Lilly and Company (JOBS), AstraZeneca PLC (JOBS) Anti-Psychotics for Dementia
November 12, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- More than 140,000 dementia patients in Britain are given anti-psychotic drugs needlessly and overprescribing of the medicines is linked to an extra 1,800 deaths in elderly people each year, a report said on Thursday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
AstraZeneca
Johnson & Johnson Family of Companies
Eli Lilly and Company
MORE ON THIS TOPIC
Neuropsychiatric disorders
Otsuka’s drug eases symptom burden, anxiety in ADHD as FDA verdict nears
June 26, 2026
·
2 min read
·
Tristan Manalac
Pipeline
Moderna looks out to R&D ‘horizons’ as 2028 break-even goal looms
June 26, 2026
·
2 min read
·
Tristan Manalac
FDA
BIO 2026: FDA’s IND initiative is a step toward normalization after slipshod year
June 25, 2026
·
3 min read
·
Jef Akst
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
June 25, 2026
·
1 min read
·
Jennifer C. Smith-Parker